12:00 AM
 | 
Aug 25, 2008
 |  BioCentury  |  Emerging Company Profile

Melior: Multiplexed reprofiling

Emerging Company Profile

Melior Discovery Inc. has developed a multiplexed in vivo reprofiling system that it believes is more efficient than one-off in vivo models and more predictive than cell-based in vitro approaches. Last week, the company announced a fourth fee-for-service deal with a pharma partner, this time AstraZeneca plc. Revenue from Melior’s service deals will be used to build out its own pipeline of reprofiled molecules.

The company’s theraTrace system uses 35 assays which President and CEO Andrew Reaume said “every pharma company knows about and that have proven to be highly predictive of clinical success.” The assays measure the effects of compounds on biomarkers associated with 35 different diseases; for example, glucose for diabetes.

According to Reaume, what’s unique about theraTrace is that it can run four or five different assays together in a single animal while avoiding interactions that would compromise the data. The company hasn’t disclosed details about the platform, including how the assays...

Read the full 791 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >